Challenges of modulating the risk of bronchopulmonary dysplasia in clinical trials - Authors' reply

Lancet Respir Med. 2024 Aug;12(8):e44. doi: 10.1016/S2213-2600(24)00173-5. Epub 2024 Jun 12.

Authors

John Lowe¹, Janet Berrington², David Gillespie¹, Mark Turner³, Sailesh Kotecha⁴

Affiliations

¹ Centre For Trials Research, Cardiff University, Cardiff, UK.
² Neonatal Medicine, Newcastle upon Tyne NHS Foundation Trust, Newcastle upon Tyne, UK; Translational and Clinical Research Institute, Newcastle University, Newcastle, UK.
³ Women and Children's Health, University of Liverpool, Liverpool, UK.
⁴ Department of Child Health, Cardiff University School of Medicine, Cardiff CF14 4XN, UK. Electronic address: kotechas@cardiff.ac.uk.

PMID: 38878789
DOI: 10.1016/S2213-2600(24)00173-5

No abstract available

Publication types

Letter

MeSH terms

Bronchopulmonary Dysplasia* / prevention & control
Clinical Trials as Topic
Humans
Infant, Newborn
Infant, Premature
Risk Factors